pancreatitis

Camostat mesylate (FOY-S980) is a trypsin-like protease inhibitor and inhibits airway epithelial sodium channel (ENaC) function.

Visnagin has acute hypotensive, anti-inflammatory, and neuroprotective effects, it protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase.

Ceruletide is a decapeptide that serves as a safe and effective cholecystokinin receptor agonist, exerting a direct spasmogenic effect on the gallbladder muscle and bile ducts, and is commonly used to establish pancreatitis models.

Taurocholic acid (N-Choloyltaurine) is a bile acid involved in fat emulsification, possessing notable biological and immunomodulatory activities. It can inhibit bile duct injury induced by hepatic artery ligation by upregulating VEGF-A expression and protect cholangiocytes from TNF-α-induced damage via a PI3K-mediated pathway, and is commonly used to induce pancreatitis models.

(Iso)-FK-480 is a novel orally available cholecystokinin A (CCK-A) antagonist for investigational treatment of chronic pancreatitis.

Ono-3307 mesylate is a protease inhibitor with inhibitory effects on a variety of proteases.Ono-3307 mesylate has significant protective effects against liver injury in rats and inhibits the deposition of radiofibrillar proteins in the kidneys and lungs.PF-184298 is a protease inhibitor with potential antioxidant effects in plasma and adipose tissue.PF-184298 can be used in the study of pancreatitis.

Pranazepide (FK 480) is a small molecule cholecystokinin receptor antagonist used to study digestive disorders and pancreatitis.

Patamostat mesylate (E-3123) is a potent protease inhibitor with IC50 values of 39 nM for trypsin, 950 nM for plasmin, and 1.9 μM for thrombin. This compound demonstrates promising potential in suppressing the pathogenesis and development of acute pancreatitis.

Patamostat HCl is a highly potent and selective small molecule protease (protease) inhibitor that inhibits trypsin, fibrinolytic enzymes, and thrombin with IC50 values of 39 nM, 950 nM, and 1.9 μM, respectively.Patamostat HCl is used in the study of acute pancreatitis.

Gabexate mesylate (FOY) is a serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.

L-Arginine hydrochloride serve as substrates and nitrogen donors for endothelial nitric oxide synthase (eNOS) to produce nitric oxide (NO). They are transported into vascular smooth muscle cells via cationic amino acid transporters, where they are metabolized into NO, polyamines, or L-proline. As effective vasodilators, they are commonly used to induce experimental acute pancreatitis models.

Taurocholic acid sodium salt hydrate is a bile acid sodium salt hydrate that participates in fat emulsification and can be used to establish pancreatitis models.

L-Arginine (L-Arg) is a substrate of endothelial nitric oxide synthase (eNOS). L-Arginine is transported to vascular smooth muscle cells via a family of cationic amino acid transporters and is metabolized to nitric oxide, polyamines, or L-proline. L-Arginine is a potent vasodilator and can be used to induce experimental acute pancreatitis.

Acifluorfen is a protoporphyrinogen oxidase (PPO) inhibitor herbicide that promotes the accumulation of protoporphyrin IX. It induces liver tumors, liver injury, and cardiac dysfunction in rodents, and causes severe photooxidative damage to pigments and lipids in susceptible plants. It can be used to induce hepatitis and pancreatitis.

Sodium taurocholate is a biologically active compound that can inhibit bile duct injury induced by hepatic artery ligation by upregulating VEGF-A expression. It also exhibits immunomodulatory effects and can be used to induce pancreatitis models.

(±)-C3001a is the racemic mixture of C3001a (CAS: 2415154-29-7). C3001a is a selective activator of the TREK channel within the two-pore-domain potassium channel (K2P) family. C3001a specifically binds to a cryptic site formed by P1 and TM4 in TREK-1, thereby promoting the selective regulation of TREK-1 activity. C3001a targets TREK channels in the peripheral nervous system, reducing the excitability of pain-sensing neurons.

Patamostat (E-3123) is a potent protease inhibitor that effectively inhibits trypsin, plasmin, and thrombin with IC50 values of 39 nM, 950 nM, and 1.9 µM, respectively. Research suggests it might suppress the pathogenesis and development of acute pancreatitis [1] [2].

ATN-161 acetate, a pentapeptide compound derived from the synergistic region of fibronectin, is a non-competitive integrin-alpha5 antagonist with antitumor activity that attenuates the pathology of caerulein-induced acute pancreatitis.

Diarylalkane derivative 1 is utilized in pancreatitis research.

LQ-38 is an orally active, soluble epoxide hydrolase (sEH) inhibitor with an IC50 value of 5.2 nM. It has shown anti-inflammatory activity in rat foot edema models and in mouse models of acute pancreatitis, and exhibits analgesic effects in acetic acid-induced mouse writhing models.

sEH inhibitor-19 (Compound (R)-14i) is an orally active soluble epoxide hydrolase (sEH) inhibitor with an IC50 of 1.2 nM. This compound suppresses the expression of TNF-α and IL-6 and exhibits anti-inflammatory effects in mouse models of acute pancreatitis and Carrageenan-induced edema.

CYP2E1-IN-1 (Compound 10) is an orally active inhibitor of cytochrome P450 2E1 (CYP2E1) with a dissociation constant (Kd) of 7.02 μM, an IC50 of 1.64 μM, and a Ki of 0.897 μM. It alleviates pancreatic damage by activating the Nrf2/HO-1 signaling pathway and inhibiting ROS production. CYP2E1-IN-1 demonstrates significant anti-inflammatory and antioxidant properties, effectively reducing inflammation and oxidative stress in severe acute pancreatitis (SAP). It is suitable for the study of SAP and other inflammation-related conditions.

3,4-DAA has anti-inflammatory activity, ameliorates acute hepatic allograft injury, and alleviates severe acute pancreatitis by inhibiting intestinal barrier dysfunction and NF-κB activation.3,4-DAA inhibits EOC20 cell-inducible nitric oxide synthase (iNOS) induced by IFN-γ and lipopolysaccharide.

Crambene results in the induction of apoptosis by protects mice against acute pancreatitis via anti-inflammatory pathways.